SNNA Sienna Biopharmaceuticals Inc.

2
+0.03  (+2%)
Previous Close 1.97
Open 1.95
Price To Book 2.27
Market Cap 60751640
Shares 30,375,820
Volume 289,989
Short Ratio
Av. Daily Volume 364,229

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data met non-inferiority primary endpoint - February 8, 2019. Seeking partner for further advancement.
SNA-001
Reduction of light-pigmented hair
Phase 3 data released July 30, 2018 did not meet primary endpoint.
SNA-001
Acne
Phase 2b trial did not meet primary endpoint. Phase 3 trial to be initiated 2H 2019.
SNA-120
Pruritus associated with psoriasis
Phase 1/2 data released August 27, 2018.
SNA-125
Psoriasis
Phase 2 trial planned.
SNA-125
Atopic dermatitis

Latest News

  1. Sienna Biopharmaceuticals Promotes Alexander Azoy to Chief Financial Officer and Appoints Sean Andrews to Leadership Team as Vice President, Investor Relations
  2. Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
  3. Sienna Biopharmaceuticals to Present at Cowen and Company Health Care Conference
  4. Why A Secondary Offering Is Often Negative For Stocks
  5. Sienna Biopharmaceuticals Prices Public Offering of Common Stock
  6. The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering
  7. Sienna Biopharmaceuticals Announces Proposed Public Offering of Common Stock
  8. 4 Tech Stocks Leading The Pack On Friday (2/8/19)
  9. Sienna Biopharmaceuticals’ Novel Silver Photoparticle Technology SNA-001 Successfully Removes Light Hair When Used with Common Laser System
  10. Sienna Biopharmaceuticals® to Present at Dermatology Summit and J.P. Morgan Healthcare Conference
  11. Do Directors Own Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) Shares?
  12. Hedge Funds Are Selling Paratek Pharmaceuticals Inc (PRTK)
  13. Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference
  14. Sienna Biopharmaceuticals Announces Its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) Demonstrated Significant Impact on Psoriasis in Phase 2b Study and Plans to Initiate Phase 3 Psoriasis Trials in Second Half of 2019
  15. Detailed Research: Economic Perspectives on Pernix Therapeutics, Hallador Energy, Vince Holding, Tuesday Morning, Information Services Group, and Sienna Biopharmaceuticals — What Drives Growth in Today's Competitive Landscape
  16. Sienna Biopharmaceuticals® Reports Third Quarter 2018 Financial Results
  17. Benzinga Pro's 5 Stocks To Watch Today